Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. A comparative study

Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 4; p. 453
Main Authors Toussirot, Eric, Grandclément, Emilie, Gaugler, Béatrice, Michel, Fabrice, Wendling, Daniel, Saas, Philippe, Dumoulin, Gilles
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 01.01.2013
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2013.00453

Cover

Abstract Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal, and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC), with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS, and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA (p = 0.01) while visceral fat was also increased, but only in women (p = 0.01). Patients with AS tended to have lower total fat mass (p = 0.07) and higher lean mass compared to HC (p = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS (p < 0.01), while total adiponectin and the ratio of HMW to total adiponectin were both increased in RA (p < 0.01). There were no changes in serum resistin and ghrelin in any group of patients. HOMA-IR and the atherogenic index were not modified in RA and AS. These results confirm that body composition was altered in RA and AS, affecting distinct soft tissue compartments. The effect of the increased visceral adipose tissue on cardiovascular risk is presumably attenuated by the favorable cardiometabolic profile in women with RA, as suggested by the normal HOMA-IR and atherogenic index.
AbstractList Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC) with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry (DXA) to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA (p= 0.01) while visceral fat was also increased, but only in women (p=0.01). Patients with AS tended to have lower total fat mass (p=0.07) and higher lean mass compared to HC (p = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS (p
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal, and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC), with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS, and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA (p = 0.01) while visceral fat was also increased, but only in women (p = 0.01). Patients with AS tended to have lower total fat mass (p = 0.07) and higher lean mass compared to HC (p = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS (p < 0.01), while total adiponectin and the ratio of HMW to total adiponectin were both increased in RA (p < 0.01). There were no changes in serum resistin and ghrelin in any group of patients. HOMA-IR and the atherogenic index were not modified in RA and AS. These results confirm that body composition was altered in RA and AS, affecting distinct soft tissue compartments. The effect of the increased visceral adipose tissue on cardiovascular risk is presumably attenuated by the favorable cardiometabolic profile in women with RA, as suggested by the normal HOMA-IR and atherogenic index.Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal, and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC), with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS, and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA (p = 0.01) while visceral fat was also increased, but only in women (p = 0.01). Patients with AS tended to have lower total fat mass (p = 0.07) and higher lean mass compared to HC (p = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS (p < 0.01), while total adiponectin and the ratio of HMW to total adiponectin were both increased in RA (p < 0.01). There were no changes in serum resistin and ghrelin in any group of patients. HOMA-IR and the atherogenic index were not modified in RA and AS. These results confirm that body composition was altered in RA and AS, affecting distinct soft tissue compartments. The effect of the increased visceral adipose tissue on cardiovascular risk is presumably attenuated by the favorable cardiometabolic profile in women with RA, as suggested by the normal HOMA-IR and atherogenic index.
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal, and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC), with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS, and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA ( p  = 0.01) while visceral fat was also increased, but only in women ( p  = 0.01). Patients with AS tended to have lower total fat mass ( p  = 0.07) and higher lean mass compared to HC ( p  = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS ( p  < 0.01), while total adiponectin and the ratio of HMW to total adiponectin were both increased in RA ( p  < 0.01). There were no changes in serum resistin and ghrelin in any group of patients. HOMA-IR and the atherogenic index were not modified in RA and AS. These results confirm that body composition was altered in RA and AS, affecting distinct soft tissue compartments. The effect of the increased visceral adipose tissue on cardiovascular risk is presumably attenuated by the favorable cardiometabolic profile in women with RA, as suggested by the normal HOMA-IR and atherogenic index.
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability to release a wide range of products involved in physiologic functions, but also in various pathological processes, including the inflammatory/immune response. RA and AS are both associated with the development of cardiovascular complications. It is has been established that central/abdominal, and particularly intra-abdominal or visceral adiposity is closely linked to cardiovascular events. Thus, in this study, we aimed to evaluate the body composition of patients with RA or AS compared to healthy controls (HC), with a special emphasis on the visceral region. In parallel, we measured adipose products or adipokines, namely leptin, adiponectin and its high molecular weight (HMW) isoform, resistin, and ghrelin, a gastric peptide that plays a role in energetic balance. The homeostasis model assessment for insulin resistance (HOMA-IR) and atherogenic index were used to evaluate cardiovascular risk. One hundred and twelve subjects were enrolled (30 patients with RA, 31 with AS, and 51 HC). Body composition was measured using dual-energy X-ray absorptiometry to determine total fat mass and lean mass, adiposity, fat in the android and gynoid regions, and visceral fat. Patients and HC did not differ in terms of body mass index. On the contrary, adiposity was increased in RA (p = 0.01) while visceral fat was also increased, but only in women (p = 0.01). Patients with AS tended to have lower total fat mass (p = 0.07) and higher lean mass compared to HC (p = 0.07). Leptin and leptin/fat mass were decreased in male patients with AS (p < 0.01), while total adiponectin and the ratio of HMW to total adiponectin were both increased in RA (p < 0.01). There were no changes in serum resistin and ghrelin in any group of patients. HOMA-IR and the atherogenic index were not modified in RA and AS. These results confirm that body composition was altered in RA and AS, affecting distinct soft tissue compartments. The effect of the increased visceral adipose tissue on cardiovascular risk is presumably attenuated by the favorable cardiometabolic profile in women with RA, as suggested by the normal HOMA-IR and atherogenic index.
Author Toussirot, Éric
AuthorAffiliation 2 Department of Rheumatology, University Hospital of Besançon , Besançon , France
6 University Hospital of Besançon, Endocrine and Metabolic Biochemistry , Besançon , France
11 Department of Physical Medicine and Rehabilitation, University Hospital of Besançon , Besançon , France
10 Université de Franche Comté, UMR1098 , Besançon , France
9 Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098 , Besançon , France
3 Department of Therapeutics, University of Franche Comté , Besançon , France
1 University Hospital of Besançon, Clinical Investigation Center for Biotherapy INSERM CBT-506, FHU INCREASE , Besançon , France
5 LabEX LipSTIC, ANR-11-LABX-0021 , Besançon , France
8 UMR1098, INSERM , Besançon , France
7 University of Franche Comté, UPRES EA 3920 “Cardiovascular Pathophysiology and Prevention”, SFR FED 4234 , Besançon , France
4 University of Franche Comté, UPRES EA 4266 «Pathogens and Inflammation» SFR FED 4234 , Besançon , France
AuthorAffiliation_xml – name: 7 University of Franche Comté, UPRES EA 3920 “Cardiovascular Pathophysiology and Prevention”, SFR FED 4234 , Besançon , France
– name: 2 Department of Rheumatology, University Hospital of Besançon , Besançon , France
– name: 10 Université de Franche Comté, UMR1098 , Besançon , France
– name: 11 Department of Physical Medicine and Rehabilitation, University Hospital of Besançon , Besançon , France
– name: 4 University of Franche Comté, UPRES EA 4266 «Pathogens and Inflammation» SFR FED 4234 , Besançon , France
– name: 9 Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098 , Besançon , France
– name: 5 LabEX LipSTIC, ANR-11-LABX-0021 , Besançon , France
– name: 3 Department of Therapeutics, University of Franche Comté , Besançon , France
– name: 6 University Hospital of Besançon, Endocrine and Metabolic Biochemistry , Besançon , France
– name: 1 University Hospital of Besançon, Clinical Investigation Center for Biotherapy INSERM CBT-506, FHU INCREASE , Besançon , France
– name: 8 UMR1098, INSERM , Besançon , France
Author_xml – sequence: 1
  givenname: Eric
  surname: Toussirot
  fullname: Toussirot, Eric
  organization: University Hospital of Besançon, Clinical Investigation Center for Biotherapy INSERM CBT-506, FHU INCREASE , Besançon , France ; Department of Rheumatology, University Hospital of Besançon , Besançon , France ; Department of Therapeutics, University of Franche Comté , Besançon , France ; University of Franche Comté, UPRES EA 4266 «Pathogens and Inflammation» SFR FED 4234 , Besançon , France ; LabEX LipSTIC, ANR-11-LABX-0021 , Besançon , France
– sequence: 2
  givenname: Emilie
  surname: Grandclément
  fullname: Grandclément, Emilie
  organization: University Hospital of Besançon, Endocrine and Metabolic Biochemistry , Besançon , France ; University of Franche Comté, UPRES EA 3920 "Cardiovascular Pathophysiology and Prevention", SFR FED 4234 , Besançon , France
– sequence: 3
  givenname: Béatrice
  surname: Gaugler
  fullname: Gaugler, Béatrice
  organization: LabEX LipSTIC, ANR-11-LABX-0021 , Besançon , France ; UMR1098, INSERM , Besançon , France ; Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098 , Besançon , France ; Université de Franche Comté, UMR1098 , Besançon , France
– sequence: 4
  givenname: Fabrice
  surname: Michel
  fullname: Michel, Fabrice
  organization: Department of Physical Medicine and Rehabilitation, University Hospital of Besançon , Besançon , France
– sequence: 5
  givenname: Daniel
  surname: Wendling
  fullname: Wendling, Daniel
  organization: Department of Rheumatology, University Hospital of Besançon , Besançon , France ; University of Franche Comté, UPRES EA 4266 «Pathogens and Inflammation» SFR FED 4234 , Besançon , France
– sequence: 6
  givenname: Philippe
  surname: Saas
  fullname: Saas, Philippe
  organization: University Hospital of Besançon, Clinical Investigation Center for Biotherapy INSERM CBT-506, FHU INCREASE , Besançon , France ; LabEX LipSTIC, ANR-11-LABX-0021 , Besançon , France ; UMR1098, INSERM , Besançon , France ; Etablissement Français du Sang Bourgogne Franche-Comté, UMR1098 , Besançon , France ; Université de Franche Comté, UMR1098 , Besançon , France
– sequence: 7
  givenname: Gilles
  surname: Dumoulin
  fullname: Dumoulin, Gilles
  organization: University Hospital of Besançon, Endocrine and Metabolic Biochemistry , Besançon , France ; University of Franche Comté, UPRES EA 3920 "Cardiovascular Pathophysiology and Prevention", SFR FED 4234 , Besançon , France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24379815$$D View this record in MEDLINE/PubMed
BookMark eNp1Uktv1DAQtlARLaV3TshHLrvEzzgXpKriUakSB-BsOfZk121iB9up2H-Pd7dFLRK-2DPzPWTN9xqdhBgAobekWTOmug-Dn6ZlTRvC1k3DBXuBzoiUfMUo5SdP3qfoIufbph7eMcbEK3RKOWs7RcQZ-v0d0jJh4_wc73yAjE1wxzIDLj7nBbDzuSTfL8XHgH3AaQvLZEr0FZnKNvmKO_LC3W6M2YcNznMMbjfuR2t8iW2cZpNM8feAc1nc7g16OZgxw8XDfY5-fv704-rr6ubbl-ury5uV5ZKWFeFCGMII67nqyFCb0DDLwMreSsdE6_ggnOUWWqCuVc4y6TgQqYAZKYCdo-ujrovmVs_JTybtdDReHxoxbXT9g7cjaE7sQMBSkIpxB9XQKmVhGFrVU2dp1fp41JqXfgJnIZRkxmeizyfBb_Um3mumJGkVqQLvHwRS_LVALnry2cI4mgBxyZrwrmklFYJV6LunXn9NHldXAfIIsCnmnGDQ1hezX1G19qMmjd7HRB9iovcx0YeYVGLzD_FR-7-UPw4pxWU
CitedBy_id crossref_primary_10_1080_25785826_2021_1948689
crossref_primary_10_1016_j_canlet_2018_03_011
crossref_primary_10_1016_j_lpm_2015_03_023
crossref_primary_10_3390_biomedicines11020536
crossref_primary_10_3390_biomedicines11112998
crossref_primary_10_3389_fendo_2019_00252
crossref_primary_10_1007_s00403_017_1755_y
crossref_primary_10_3899_jrheum_140439
crossref_primary_10_1007_s10067_015_2955_5
crossref_primary_10_1517_14740338_2015_1007041
crossref_primary_10_3389_fendo_2020_606560
crossref_primary_10_5114_reum_2015_53998
crossref_primary_10_3390_ijms20184633
crossref_primary_10_3390_ijms23052859
crossref_primary_10_1002_jcla_22595
crossref_primary_10_1016_j_intimp_2017_09_029
crossref_primary_10_1016_j_lfs_2015_05_001
crossref_primary_10_1177_0300060517708693
crossref_primary_10_1016_j_monrhu_2017_11_003
crossref_primary_10_1186_ar4538
crossref_primary_10_1186_ar4537
crossref_primary_10_1016_j_rhum_2015_08_003
crossref_primary_10_3899_jrheum_140780
crossref_primary_10_1002_ajhb_22583
crossref_primary_10_1016_j_crad_2018_06_008
crossref_primary_10_1016_j_lfs_2017_12_003
crossref_primary_10_1016_j_jbspin_2015_04_010
crossref_primary_10_4078_jrd_2023_0005
crossref_primary_10_1177_20503121221085821
crossref_primary_10_1186_s13075_017_1350_9
crossref_primary_10_3390_ijms19092717
crossref_primary_10_3389_fimmu_2021_665208
crossref_primary_10_3889_oamjms_2022_8208
crossref_primary_10_3899_jrheum_170094
crossref_primary_10_1136_postgradmedj_2018_136372
crossref_primary_10_3389_fmed_2021_782150
crossref_primary_10_1093_rheumatology_keaa720
crossref_primary_10_1016_j_cyto_2015_04_004
crossref_primary_10_1016_j_arcmed_2016_03_001
ContentType Journal Article
Copyright Copyright © 2013 Toussirot, Grandclément, Gaugler, Michel, Wendling, Saas, Dumoulin and CBT-506. 2013
Copyright_xml – notice: Copyright © 2013 Toussirot, Grandclément, Gaugler, Michel, Wendling, Saas, Dumoulin and CBT-506. 2013
CorporateAuthor CBT-506
CorporateAuthor_xml – name: CBT-506
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2013.00453
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_41cf1ec2e6834de489c88ceff78b2dc2
PMC3861781
24379815
10_3389_fimmu_2013_00453
Genre Journal Article
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
IPNFZ
KQ8
M48
M~E
OK1
PGMZT
RIG
RNS
RPM
NPM
7X8
5PM
ID FETCH-LOGICAL-c462t-1455a1313b4891fc46e03c3ec6bc6d357d4f5dc4ce7e2d78dc36d4e168e3a65e3
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:01:21 EDT 2025
Thu Aug 21 14:10:12 EDT 2025
Fri Sep 05 12:40:19 EDT 2025
Thu Apr 03 06:55:42 EDT 2025
Thu Apr 24 22:57:09 EDT 2025
Tue Jul 01 01:57:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords adiponectin
body composition
cardiovascular risk
leptin
visceral fat
fat mass
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-1455a1313b4891fc46e03c3ec6bc6d357d4f5dc4ce7e2d78dc36d4e168e3a65e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Inflammation, a section of the journal Frontiers in Immunology.
Reviewed by: Giamila Fantuzzi, University of Illinois at Chicago, USA; Frédéric Velard, Université de Reims Champagne-Ardenne, France
Edited by: Oreste Gualillo, Santiago University Clinical Hospital, Spain
OpenAccessLink https://doaj.org/article/41cf1ec2e6834de489c88ceff78b2dc2
PMID 24379815
PQID 1490762553
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_41cf1ec2e6834de489c88ceff78b2dc2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3861781
proquest_miscellaneous_1490762553
pubmed_primary_24379815
crossref_citationtrail_10_3389_fimmu_2013_00453
crossref_primary_10_3389_fimmu_2013_00453
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-01-01
PublicationDateYYYYMMDD 2013-01-01
PublicationDate_xml – month: 01
  year: 2013
  text: 2013-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2013
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References 16732021 - Diabetes Care. 2006 Jun;29(6):1357-62
3358796 - Arthritis Rheum. 1988 Mar;31(3):315-24
19714593 - Arthritis Rheum. 2009 Sep 15;61(9):1248-56
6426576 - Br Med J (Clin Res Ed). 1984 May 12;288(6428):1401-4
16603581 - Rheumatology (Oxford). 2006 Nov;45(11):1385-8
19565493 - Arthritis Rheum. 2009 Jul;60(7):1906-14
15292530 - Rheumatology (Oxford). 2004 Oct;43(10):1219-23
18512711 - Arthritis Rheum. 2008 Jun 15;59(6):807-15
23806868 - Int J Biochem Cell Biol. 2013 Oct;45(10):2163-72
17260105 - Clin Rheumatol. 2007 Sep;26(9):1427-32
23666343 - Biogerontology. 2013 Jun;14(3):261-72
17456023 - Curr Med Chem. 2007;14(10):1095-100
18759279 - Arthritis Rheum. 2008 Sep;58(9):2632-41
9159537 - Br J Rheumatol. 1997 Apr;36(4):444-8
6231933 - Arthritis Rheum. 1984 Apr;27(4):361-8
21292736 - Rheumatology (Oxford). 2011 Jul;50(7):1250-8
11296956 - J Rheumatol. 2001 Mar;28(3):547-9
24043573 - Horm Metab Res. 2014 Jan;46(1):41-7
17343838 - Clin Chim Acta. 2007 May 1;380(1-2):24-30
22282048 - Obesity (Silver Spring). 2012 Jun;20(6):1313-8
14623951 - Rheumatology (Oxford). 2004 Mar;43(3):306-10
15466894 - Rheumatology (Oxford). 2005 Jan;44(1):120-5
20959355 - Rheumatology (Oxford). 2011 Mar;50(3):450-62
21140266 - Rheumatol Int. 2012 Mar;32(3):699-702
16414972 - Ann Rheum Dis. 2006 Sep;65(9):1198-201
21618146 - Swiss Med Wkly. 2011 May 27;141:w13211
19602478 - Rheumatology (Oxford). 2009 Sep;48(9):1128-32
22876925 - Curr Med Chem. 2012;19(32):5474-80
17884449 - Metabolism. 2007 Oct;56(10):1383-9
12933646 - Endocrinology. 2003 Sep;144(9):3765-73
3899825 - Diabetologia. 1985 Jul;28(7):412-9
22213726 - Arthritis Care Res (Hoboken). 2012 Jan;64(1):101-7
11762933 - Arthritis Rheum. 2001 Dec;44(12):2737-45
1464859 - J Rheumatol. 1992 Oct;19(10):1505-10
22949540 - Circulation. 2012 Sep 4;126(10):1301-13
22584415 - Eur J Nutr. 2012 Aug;51(5):513-28
21567382 - Arthritis Rheum. 2011 Sep;63(9):2567-74
11511757 - Rheumatology (Oxford). 2001 Aug;40(8):882-8
15890981 - Circ Res. 2005 May 13;96(9):939-49
References_xml – reference: 15890981 - Circ Res. 2005 May 13;96(9):939-49
– reference: 20959355 - Rheumatology (Oxford). 2011 Mar;50(3):450-62
– reference: 17884449 - Metabolism. 2007 Oct;56(10):1383-9
– reference: 22213726 - Arthritis Care Res (Hoboken). 2012 Jan;64(1):101-7
– reference: 23666343 - Biogerontology. 2013 Jun;14(3):261-72
– reference: 19565493 - Arthritis Rheum. 2009 Jul;60(7):1906-14
– reference: 22584415 - Eur J Nutr. 2012 Aug;51(5):513-28
– reference: 21140266 - Rheumatol Int. 2012 Mar;32(3):699-702
– reference: 17343838 - Clin Chim Acta. 2007 May 1;380(1-2):24-30
– reference: 11762933 - Arthritis Rheum. 2001 Dec;44(12):2737-45
– reference: 19602478 - Rheumatology (Oxford). 2009 Sep;48(9):1128-32
– reference: 18759279 - Arthritis Rheum. 2008 Sep;58(9):2632-41
– reference: 24043573 - Horm Metab Res. 2014 Jan;46(1):41-7
– reference: 23806868 - Int J Biochem Cell Biol. 2013 Oct;45(10):2163-72
– reference: 21567382 - Arthritis Rheum. 2011 Sep;63(9):2567-74
– reference: 16603581 - Rheumatology (Oxford). 2006 Nov;45(11):1385-8
– reference: 16414972 - Ann Rheum Dis. 2006 Sep;65(9):1198-201
– reference: 21292736 - Rheumatology (Oxford). 2011 Jul;50(7):1250-8
– reference: 16732021 - Diabetes Care. 2006 Jun;29(6):1357-62
– reference: 11511757 - Rheumatology (Oxford). 2001 Aug;40(8):882-8
– reference: 19714593 - Arthritis Rheum. 2009 Sep 15;61(9):1248-56
– reference: 22282048 - Obesity (Silver Spring). 2012 Jun;20(6):1313-8
– reference: 15466894 - Rheumatology (Oxford). 2005 Jan;44(1):120-5
– reference: 22949540 - Circulation. 2012 Sep 4;126(10):1301-13
– reference: 22876925 - Curr Med Chem. 2012;19(32):5474-80
– reference: 11296956 - J Rheumatol. 2001 Mar;28(3):547-9
– reference: 9159537 - Br J Rheumatol. 1997 Apr;36(4):444-8
– reference: 6426576 - Br Med J (Clin Res Ed). 1984 May 12;288(6428):1401-4
– reference: 3899825 - Diabetologia. 1985 Jul;28(7):412-9
– reference: 1464859 - J Rheumatol. 1992 Oct;19(10):1505-10
– reference: 15292530 - Rheumatology (Oxford). 2004 Oct;43(10):1219-23
– reference: 18512711 - Arthritis Rheum. 2008 Jun 15;59(6):807-15
– reference: 21618146 - Swiss Med Wkly. 2011 May 27;141:w13211
– reference: 6231933 - Arthritis Rheum. 1984 Apr;27(4):361-8
– reference: 14623951 - Rheumatology (Oxford). 2004 Mar;43(3):306-10
– reference: 12933646 - Endocrinology. 2003 Sep;144(9):3765-73
– reference: 17456023 - Curr Med Chem. 2007;14(10):1095-100
– reference: 17260105 - Clin Rheumatol. 2007 Sep;26(9):1427-32
– reference: 3358796 - Arthritis Rheum. 1988 Mar;31(3):315-24
SSID ssj0000493335
Score 2.2214012
Snippet Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are inflammatory rheumatic diseases that may modify body composition. Adipose tissue has the ability...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 453
SubjectTerms Adiponectin
Body Composition
fat mass
Immunology
Leptin
visceral fat
SummonAdditionalLinks – databaseName: DOAJ Open Access Full Text
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9SEHwR6-fZKhF88WG9zedmH2tpKYI-Wejbkk0m3Fpvr9ztgv3vm0m2552Ivvi42QkJM5PMTDL5DSHvpbWls8EUkldlIXVbFzUPrDCuEjZ6dMwzfDv85au-uJSfr9TVTqkvzAnL8MCZcXPJXGDgOGgjpAdpameMgxAq03Lv0u4bzdhOMPU9-71CCJXvJWMUVs9Dt1yOmMqFiKZSiT07lOD6_-Rj_p4quWN7zp-Qx5PTSE_yZA_JA-ifkoe5jOTtM_IzLvhxSa3vblbXmMZObe_z5wbokFhLPSLkTsWtaNfT9QLG6K2uuki5HhYJ2yj3669jEI9HCBTTZ_0tJshtPtIT6n4hhdMES_ucXJ6ffTu9KKaKCoWTmg8FopJbJphoIx9ZiI1QCifA6dZpL1TlZVDeSQcVcF8Z74T2Epg2IKxWIF6Qg37VwytCrRFljWAzQdTRCWFWOwU8UhmoOQvljMzv-du4CW4cq178aGLYgRJpkkQalEiTJDIjH7Y9bjLUxl9oP6HItnQIkp0aouo0k-o0_1KdGXl3L_AmLiq8KbE9rMZNjIfqMloJhQO9zAqwHSohOBqmZqTaU429uez_6btFAu4WBh9kstf_Y_JH5BFPlTnwNOiYHAzrEd5E_2ho36alcAershOH
  priority: 102
  providerName: Directory of Open Access Journals
Title Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. A comparative study
URI https://www.ncbi.nlm.nih.gov/pubmed/24379815
https://www.proquest.com/docview/1490762553
https://pubmed.ncbi.nlm.nih.gov/PMC3861781
https://doaj.org/article/41cf1ec2e6834de489c88ceff78b2dc2
Volume 4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: KQ8
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: DIK
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: GX1
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: RPM
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: M48
  dateStart: 20101001
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagCIkL4s0WqIzEhUPa-BHHOSBUEKVCKidW2lvk9YMN7SYlm0jdf98ZJ92yaIXEJVKccRx7xpkZe_wNIe-kMak1QSeS52ki1bxICh5Yom0uDFh0zDE8O3z2XZ1O5bdZNrs9Hj0O4Gqna4f5pKbtxeHV7_VHmPAf0OMEfXsUquWyxygtBCuVmbhL7oFe4ijjZ6Ox_2uwhYWIGTeZUjIBSZbDvuXOl2zpqQjnv8sG_TuU8g_ddPKIPByNSno8SMFjcsfXT8j9Ic3k-im5gh9Cv6TGVZfNOYa5U1O74XblaReHnjpE0B2TX9Gqpu3C92DNNhVQtt0iYh8N9epzcPJxiYFieK1bYwDd6pAeU3uLJE4jbO0zMj358uPzaTJmXEisVLxLELXcMMHEXOqCBSj0qbDCWzW3yoksdzJkzkrrc89drp0VyknPlPbCqMyL52Svbmr_klCjRVogGE0QBRgpzCibeQ5U2hechXRCjm7Gt7QjHDlmxbgowS1BjpSRIyVypIwcmZD3mxqXAxTHP2g_Ics2dAiiHQua9mc5zslSMhuYt9wrLaTz0GWrtfUh5HrOneUT8vaG4SVMOtxJMbVv-hX4S0UKWiTDhl4MArBpKiI8apZNSL4lGlvfsv2krhYR2FtoPLDJ9v-jo6_IAx4TdOCi0Guy17W9fwNmUjc_iMsLcP06YwdxJlwDpYsVIQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+adipokines+and+adipose+tissue+distribution+in+rheumatoid+arthritis+and+ankylosing+spondylitis.+A+comparative+study&rft.jtitle=Frontiers+in+immunology&rft.au=Toussirot%2C+%C3%89ric&rft.date=2013-01-01&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=4&rft_id=info:doi/10.3389%2Ffimmu.2013.00453&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2013_00453
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon